Benchmark reiterates Nexstar stock Buy rating after injunction ruling By Investing.com

Nexstar faces continued legal and antitrust pressure after a judge granted a preliminary injunction in the DirecTV/TEGNA dispute, with the court suggesting plaintiffs are likely to win on the merits. Benchmark cut its price target to $250 from $300 but kept a Buy rating, citing regulatory risk; the stock is still above the current $201 price. Nexstar also issued $1.725 billion of 7.250% senior notes due 2034 to refinance 5.625% notes due 2027, while merger activity with Tegna remains temporarily halted.

Analysis

The market is still underpricing the probability that this becomes less an earnings story and more a balance-sheet and control story. If the injunction holds, the real value leak is not just lost synergies; it is the forced separation of cash generation from ownership, which can trap capital inside an asset that cannot be integrated as planned while still carrying financing costs at holdco level. That is a negative for NXST’s equity multiple because it converts an M&A catalyst into an extended legal overhang with a financing tail risk.

The second-order winner is likely not TGNA outright, but any competing broadcaster or content distributor that can negotiate from a stronger position while management teams at NXST/TGNA are distracted. A prolonged trial window also increases the odds of a reset transaction structure—divestitures, remedies, or a partial sale of assets—rather than a clean close, which would dilute the original strategic thesis and likely force the market to price a lower takeout probability. The debt refinancing at a meaningfully higher coupon compounds this: even if the merger survives, the cost of capital has moved against the equity, so the hurdle for multiple expansion is much higher than pre-litigation assumptions.

The contrarian point is that the current selloff may still be too shallow if investors are anchoring on a binary close/no-close outcome. The more likely path is a months-long grind with incremental adverse headlines, during which the stock can de-rate without a decisive ruling because legal uncertainty suppresses both M&A optionality and fundamental visibility. Conversely, a near-term appellate stay or a negotiated remedy would create a violent squeeze, but that seems lower probability than the market may be assigning given the court’s language on merits and irreparable harm.

Key Decisions for Investors

• Short NXST on strength over the next 1-3 weeks into any bounce above the post-ruling range; target a 10-15% downside re-rate if the litigation drags and merger probability keeps falling.
• Use NXST/TGNA as a pair only if you want event exposure: long TGNA vs short NXST for 1-3 months, betting TGNA retains more value if the deal gets remediated or partially restructured while NXST bears the financing and execution burden.
• Buy NXST downside via put spreads 2-4 months out rather than outright short equity; the skew is attractive if the court process stretches and caps upside while preserving convexity into another adverse procedural step.
• Avoid chasing TGNA long until there is evidence of remedy language or appellate relief; absent that, TGNA is more a litigation asset than a clean arb and can underperform in a prolonged stalemate.